KURIYEL RALF 4
4 · REPLIGEN CORP · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
Repligen (RGEN) SVP Ralf Kuriyel Receives Restricted Stock & Options
What Happened Ralf Kuriyel, Senior Vice President of Research & Development at Repligen Corporation (RGEN), received equity compensation on March 5, 2026. The filing reports two awards: 5,284 restricted stock units (RSUs) and 5,669 derivative awards (stock options), both reported as grants (transaction code A) with a reported price/value of $0.00 (standard for compensation grants).
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 23, 2026 (filing appears late relative to the 2-business-day reporting requirement).
- Awards: 5,284 RSUs and 5,669 stock options; reported acquisition price/value $0.00 for each grant.
- Shares owned after the transaction: not specified in the provided filing.
- Footnotes:
- F1: The 5,284 RSUs vest in equal annual installments over three years starting on the first anniversary of the grant and will be settled only by delivering shares.
- F2: The 5,669 stock options vest one-third annually on March 5 of 2027, 2028, and 2029.
- Transaction code meaning: A = Award/Grant (compensation), not an open-market purchase or sale.
Context These grants are compensation awards to an executive and do not represent an open-market purchase (which might be viewed as a direct bullish signal) or sale. RSUs convert to shares when vested and delivered; the options become exercisable according to the vesting schedule noted above. The Form 4 was filed well after the transaction date, which is a reporting timeliness issue and could simply reflect administrative delay but is notable to investors.
Insider Transaction Report
- Award
Common Stock
[F1]2026-03-05+5,284→ 20,062 total - Award
Stock Option (Right to Buy)
[F2]2026-03-05+5,669→ 5,669 totalExercise: $141.91Exp: 2036-03-05→ Common Stock (5,669 underlying)
Footnotes (2)
- [F1]Mr. Kuriyel was awarded 5,284 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
- [F2]One third of the stock options will vest and become exercisable annually on March 5, 2027, March 5, 2028, and March 5, 2029.